Search Results for 'license'
-
Breaking News
Lantheus and POINT Biopharma Enter Strategic Collaboration and Exclusive License Agreement
Expands Lantheus’ portfolio with license of exclusive worldwide rights, excluding certain territories, to two late-stage therapeutic agents.11.14.22
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
Salipro Biotech, Sanofi Enter Research and License Alliance
Will leverage the Salipro platform and Sanofi's discovery programs to identify biologics against a challenging drug target.11.10.22
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Drug Discovery | Industry News
Exelixis, Catalent Enter New License Agreement for Three ADC Programs
New discovery programs focused on three oncology targets with potential to develop antibody-drug conjugates for a variety of solid tumor indications.11.03.22
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances
Rokote Laboratories Licenses Cevec’s Proprietary CAP Ad Technology
Gains non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases.09.21.22
-
Breaking News | Industry News
Oxford Biomedica Signs License and Supply Agreement
Grants the undisclosed company a non-exclusive license to utilize Oxford Biomedica’s LentiVector platform.09.08.22
-
Bio News | Breaking News | Collaborations & Alliances | GMPs/GCPs | Industry News | QA/QC | Regulatory Affairs
Chime Biologics Receives Commercial Manufacturing License
GMP commercial manufacturing license authorized by the China's NMPA demonstrates capabilities in large scale commercial production.08.02.22
-
Breaking News | Collaborations & Alliances
Kelun-Biotech Enters Collaboration & Exclusive License Agreement with MSD
Will develop an investigational antibody drug conjugate (ADC) for the treatment of solid tumors.07.26.22
-
Breaking News | Collaborations & Alliances | Drug Development | Preclinical Outsourcing
Hovione Signs Exclusive License Agreement with JIXING
JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization.05.09.22
-
Breaking News | Collaborations & Alliances
Halozyme Enters Global Collaboration and License Agreement with Chugai
Gives Chugai exclusive access to its Enhanze drug delivery technology.03.24.22
-
Biologics, Proteins, Vaccines | Breaking News | Industry News
Stelis Licenses Akston’s AKS-452 Thermostable Protein Subunit COVID Vax
Gains the right to manufacture and commercialize AmbiVax-CTM in India and over 130 countries in Asia, Latin America, and Africa.03.17.22
-
Breaking News | Collaborations & Alliances | Laboratory Testing
Charles River to License Hera BioLab’s SRG Rat (OncoRat)
Charles River will breed, distribute, sell, and market the SRG rat directly to the preclinical research community.03.17.22
-
Breaking News | Collaborations & Alliances | Drug Development | Preclinical Outsourcing
AbbVie and Gedeon Richter Enter Co-Development and License Agreement
Will research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.03.11.22
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
IASO Bio's Nanjing Mfg. Facility Licensed for CAR-T Cell Therapies
The cell production workshop designed according to cGMP requirements has the capacity of producing 3,000 batches of CAR-T cell products per year.03.03.22
-
Clinical Trials | Collaborations & Alliances
Biohaven, BMS Enter Worldwide License Agreement for Taldefgrobep
Taldefgrobep is a muscle-targeted experimental treatment developed for neuromuscular disease and offers the opportunity for combination therapy.02.25.22
-
Breaking News | Drug Development | Industry News
TrialSpark Licenses Sprifermin from Merck KGaA, Forms High Line Bio
Sprifermin promotes cartilage growth, and could be a potential disease modifying treatment for osteoarthritis.01.10.22
-
Breaking News | Industry News | R&D
Eisai Enters License Agreement with Roivant
Grants the exclusive rights for global research, development, manufacture and sale of H3B-8800 to a subsidiary of Roivant Sciences Ltd.01.06.22
-
Breaking News | Collaborations & Alliances | Drug Development
Biogen Exercises Option for Exclusive License to BIIB115
BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy.01.04.22
-
Breaking News | cGMP Manufacture
Northwest Biotherapeutics Receives MHRA Approval of License for GMP Manufacturing in UK
Enables the manufacturing of DCVax-L products to get under way at the Sawston facility.12.22.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Immatics, BMS Enter Exclusive Global License for TCR Bispecific Program
To develop and commercialize Immatics’ IMA401, which has shown anti-tumor activity with complete remissions in preclinical tumor models.12.14.21
-
Breaking News | Drug Development
Astellas Pharma and Dyno Therapeutics Sign Option and License Agreement
Will collaborate to develop next-gen AAV gene therapy vectors for skeletal and cardiac muscle.12.02.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
SOTIO, LegoChem Biosciences Enter ADC License Agreement
SOTIO licenses LegoChem Biosciences technology for five new antibody-drug conjugate programs targeting distinct tumor-associated antigens.11.16.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Cellumed and ARTES Sign Development and License Agreement
Accelerate development of GMP-grade production enzymes essential for manufacturing mRNA-based biopharmaceuticals.10.14.21
-
Breaking News | Drug Development | Industry News
RegeneRx Licensee Acquired by Korean Biopharma Group
GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharma and financial subsidiaries.09.28.21
-
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials
Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
Covers the combination of DHODH inhibitors and nucleoside analogues to treat viral infections, including Covid-19.09.22.21
-
Biologics, Proteins, Vaccines | Breaking News
Nobelpharma Signs License Agreement to Use ProBioGen’s Vaccine Production Platform
The cell-based system for vaccine production offers a cost-effective, efficient and flexible alternative to traditional vaccine production.08.12.21
-
Breaking News | cGMP Manufacture | Industry News
WuXi Biologics Receives Manufacturing License from German Health Authorities
The inspections comprised areas of cGMP manufacturing required for receiving the permit, as well as commercial production approval.07.26.21
-
Breaking News | Facilities | Industry News
SpectronRx Receives Nuclear Materials License for New Indiana Facility
Indiana-based radiopharmaceutical CDMO expands nuclear pharmacy capabilities with second location.07.22.21
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Intravacc's Inactivated Polio Vaccine Out-licensed to Sinovac
Sinovac's Eupolio vaccine (sIPV) receives market authorization from the NMPA in China.07.20.21
-
Breaking News | Collaborations & Alliances
Bicycle Therapeutics, Ionic Pharma Enter License & Collaboration Agreement
Will work together to develop targeted oligonucleotide therapeutics leveraging tissue-targeting TfR1 Bicycle technology.07.13.21
-
Breaking News | Collaborations & Alliances | Industry News
Innovent Biologics Signs License Agreement with Synaffix
Synaffix will provide proprietary ADC technologies to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate.07.01.21
-
APIs | Breaking News | cGMP Manufacture | Industry News
Onyx Scientific Receives Commercial API License for UK Facility
Allows Onyx to support API projects from pre-clinical studies to low volume commercial manufacture.Charles Sternberg, Assistant Editor 06.03.21
-
Breaking News | Collaborations & Alliances | Industry News
Elektrofi, Argenx Enter Collaboration and License Agreement
Will explore new subcutaneous formulations for therapeutic products directed at the human neonatal Fc receptor.Charles Sternberg, Assistant Editor 04.27.21
-
Biologics, Proteins, Vaccines | Breaking News | Industry News | Scale-up/Technology Transfer
SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax
Will leverage SUREtechnology Platform to generate stable, high-yield production cell lines needed for human clinical trials.Kristin Brooks 03.18.21
-
APIs | Breaking News | Formulation Development | Industry News
Tris Pharma, Athena Bioscience Enter Exclusive License Agreement
Athena gains exclusive rights to commercialize a long-acting antihypertensive product developed using Tris' proprietary technology.Kristin Brooks 02.22.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
AbbVie Licenses ProBioGen’s GlymaxX Technology
Will apply GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).Kristin Brooks 01.22.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Biogen Licenses CEVEC AAV Mfg. Technology
Biogen gains rights to ELEVECTA Technology for manufacturing of gene therapy products.Contract Pharma Staff 01.08.21
-
Breaking News | Collaborations & Alliances | Industry News
Lead Pharma and Roche Enter Collaboration & License Agreement
Will develop oral small molecules to treat immune mediated diseases.Contract Pharma Staff 11.16.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
CEVEC, Roche Ink ELEVECTA Technology License Agreement
Allows Roche to use CEVEC's ELEVECT Technology for AAV vector manufacturing for its portfolio of gene therapy products.Contract Pharma Staff 11.11.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
CEVEC, Rznomics Ink License Agreement for CAP Technology
Rznomics will use CEVEC’s cell line technology with its trans-splicing ribozyme technology for manufacturing gene therapies targeting various cancers.10.20.20
-
Breaking News | Collaborations & Alliances | Drug Development
Sperogenix and Minoryx Enter Exclusive License Agreement
Will develop and commercialize leriglitazone in mainland China, Hong Kong and Macau.Contract Pharma Staff 09.23.20
-
Breaking News | Clinical Trials
Rain Therapeutics Licenses MDM2 Inhibitor from Daiichi Sankyo
DS-3032 has been evaluated in clinical trials for solid tumors and hematologic malignancies.Contract Pharma Staff 09.02.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
iBio Signs License Agreement with Planet Biotechnology for COVID-19 Therapeutic
ACE2-Fc directly targets coronavirus virions.Contract Pharma Staff 09.01.20
-
Breaking News | Drug Development | Industry News
Ovid, Angelini Pharma Enter Exclusive License Agreement
To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in EuropeContract Pharma Staff 07.13.20
-
Breaking News | Drug Development | Industry News
Oncology Venture Out-Licenses Clinical Assets to Smerud
Smerud will advance development of LiPlaCis in late stage metastatic breast cancer and 2X-111 in glioblastoma multiforme.Contract Pharma Staff 06.29.20
-
Breaking News | Collaborations & Alliances | Drug Development
Neurocrine Licenses Seven Takeda Compounds in $2B Deal
To develop and commercialize early-to-mid-stage psychiatry pipeline including assets for for schizophrenia, treatment-resistant depression and anhedonia.Contract Pharma Staff 06.19.20
-
Breaking News | Industry News
Wasdell Group Receives IMP License for European HQ
Enables Wasdell to expand the facility’s services.Contract Pharma Staff 05.29.20
-
Formulation Development | Industry News
SeraNovo, Carna Biosciences Enter Second License Agreement
To develop an oral formulation of a new active ingredient with enhanced bioavailability.Contract Pharma Staff 05.26.20
-
Breaking News | Industry News
Gilead, Mylan Ink Global Remdesivir License Agreement
To supply Remdesivir for potential COVID-19 treatment in 127 low- and middle-income countries.Contract Pharma Staff 05.12.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Industry News
Fujifilm Diosynth Licenses Oxgene's AAV system
Aims to deliver gene therapy products to clients with an approximate 25% lead-time reductionContract Pharma Staff 04.23.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
panCELLa, CCRM Collaborate to Benefit Academia and Industry
New iPSC master cell banks to accelerate development of novel cell therapiesContract Pharma Staff 04.21.20
